A Multicenter, Randomized, Placebo-Controlled, Double-Blind, Phase 1b Study to Evaluate the Safety, Tolerability, Pharmacokinetics, and Pharmacodynamics of DNL747 in Subjects With Amyotrophic Lateral Sclerosis
Phase of Trial: Phase I
Latest Information Update: 15 Feb 2019
At a glance
- Drugs DNL-747 (Primary)
- Indications Amyotrophic lateral sclerosis
- Focus Adverse reactions
- Sponsors Denali Therapeutics Inc
- 08 Jan 2019 According to a Denali Therapeutics media release, first patient has been dosed in this study.
- 08 Jan 2019 According to a Denali Therapeutics media release, data readout from this Phase 1b study is expected during fourth quarter of 2019.
- 08 Jan 2019 Planned number of patients changed from 16 to 26, according to a Denali Therapeutics media release